Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 101–200 of 821
Immunoporosis: Role of immune system in the pathophysiology of different types of osteoporosis
Zhang, W., Gao, R., Rong, X., Zhu, S., Cui, Y., Liu, H., & Li, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.965258 · Cited by 174
“In addition, B cells isolated from the bone marrow of postmenopausal women have been reported to secrete RANKL, contributing to osteoclastogenesis (80).”
BackgroundNLRP3 Inflammasome: A New Target for Prevention and Control of Osteoporosis?
Jiang, N., An, J., Yang, K., Liu, J., Guan, C., Ma, C., & Tang, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.752546 · Cited by 149
“Estrogen deficiency can not only directly promote osteoclasts differentiation through estrogen receptors on osteoclasts, but also indirectly stimulate nuclear factor kappa-b ligand (RANKL) on osteoblasts, T cells and B cells to promote bone resorption (4).”
BackgroundNelson, E. R., Wardell, S. E., & McDonnell, D. P. (2013) · Bone · doi:10.1016/j.bone.2012.11.011 · Cited by 134
“and stromal cells from postmenopausal women have been shown to express higher levels of RANKL on their surfaces [27,28].”
BackgroundOsteoinduction and osteoimmunology: Emerging concepts
Miron, R. J., Bohner, M., Zhang, Y., & Bosshardt, D. D. (2023) · Periodontology 2000 · doi:10.1111/prd.12519 · Cited by 157
Dempster, D. W., Lambing, C. L., Kostenuik, P. J., & Grauer, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.002 · Cited by 146
“This tumor necrosis factor superfamily member, RANK ligand (RANKL), was reported to be up-regulated in postmenopausal women in a manner that was largely corrected by estrogen supplementation.(12) RANKL is one member of the RANK/RANKL/osteoprotegerin (OPG) pathway, which was described in the late 1990s as critical in t…”
BackgroundTitanji, K., Vunnava, A., Sheth, A. N., Delille, C., Lennox, J. L., Sanford, S. E., Foster, A., Knezevic, A., Easley, K. A., Weitzmann, M. N., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004497 · Cited by 132
“RANKL was quantified by incubation with 5 mg/ml recombinant OPG-Fc (R&D systems) for 30 minutes at 4uC as previously described [43], followed by antihuman IgG Fc-PE (BD Biosciences) for another 30 minutes at 4uC.”
MethodCharacterization of circulating osteoblast lineage cells in humans
Eghbali-Fatourechi, G. Z., Mödder, U. I., Charatcharoenwitthaya, N., Sanyal, A., Undale, A. H., Clowes, J. A., Tarara, J. E., & Khosla, S. (2007) · Bone · doi:10.1016/j.bone.2006.12.064 · Cited by 142
“For each sample, 20,000 events were counted with gates applied on forward/ side light scatter over the lymphocyte-monocyte-rich region, as previously described [17].”
MethodSelf-citationOminsky, M. S., Li, X., Asuncion, F. J., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M., Tan, H.-L., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 131
“Estrogen deprivation in postmenopausal women was associated with increased RANKL protein expression by bone marrow cells, and estrogen supplementation prevented this increase.((16))”
BackgroundRegulatory roles and molecular signaling of TNF family members in osteoclasts
Feng, X. (2005) · Gene · doi:10.1016/j.gene.2005.01.014 · Cited by 152
Childhood obesity, bone development, and cardiometabolic risk factors
Pollock, N. K. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.03.016 · Cited by 154
Targeting tumor–stromal interactions in bone metastasis
Esposito, M., & Kang, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.006 · Cited by 129
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
Segovia‐Silvestre, T., Neutzsky-Wulff, A. V., Sørensen, M. G., Christiansen, C., Bollerslev, J., Karsdal, M. A., & Henriksen, K. (2008) · Human Genetics · doi:10.1007/s00439-008-0583-8 · Cited by 140
McNamara, L. M. (2010) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0282 · Cited by 124
“RANKL expression is upregulated in osteoporotic bone (Ikeda et al. 2001; Eghbali-Fatourechi et al. 2003) and MCSF expression is increased in primary cells harvested from the animal models of post-menopausal osteoporosis (Srivastava et al.”
BackgroundEstrogens in rheumatoid arthritis; the immune system and bone
Islander, U., Jochéms, C., Lagerquist, M. K., Forsblad‐d’Elia, H., & Carlsten, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.018 · Cited by 150
Aromatase Inhibitors and Bone Health in Women With Breast Cancer
Chien, A. J., & Goss, P. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5382 · Cited by 133
Martin, A., de Vittoris, R., David, V., Moraes, R., Bégeot, M., Lafage-Proust, M.-H., Alexandre, C., Vico, L., & Thomas, T. (2005) · Endocrinology · doi:10.1210/en.2004-1509 · Cited by 124
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone
Ferrari, S., & Langdahl, B. L. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00935-3 · Cited by 133
Endocrine aspects of bone metastases
Hofbauer, L. C., Rachner, T. D., Coleman, R. E., & Jakob, F. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70203-1 · Cited by 132
The role of estrogen receptor α in the regulation of bone and growth plate cartilage
Börjesson, A., Lagerquist, M. K., Windahl, S. H., & Ohlsson, C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1317-1 · Cited by 131
Bone mass and mineral metabolism in HIV+ postmenopausal women
Yin, M. T., Dobkin, J. F., Brudney, K. F., Becker, C., Zadel, J. L., Manandhar, M., Addesso, V., & Shane, E. J. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1845-0 · Cited by 119
“Furthermore, pharmacologic levels of certain PIs, such as ritonavir and saquinavir, appear to increase RANKL activity by abrogating physiologic, IFN-c-linked blocks to the degradation of the RANKL-signaling adapter protein, TNF receptor-associated protein 6 (TRAF-6) [38].”
BackgroundInfluentialDelmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 131
McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., & Miller, P. D. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2052-4 · Cited by 115
“Increased production of RANK ligand is implicated as a cause of increased bone remodeling in postmenopausal women [7, 8].”
BackgroundRoles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 123
Dar, H. Y., Pal, S., Shukla, P., Mishra, P. K., Tomar, G. B., Chattopadhyay, N., & Srivastava, R. K. (2018) · Nutrition · doi:10.1016/j.nut.2018.02.013 · Cited by 108
Ferroptosis in Osteocytes as a Target for Protection Against Postmenopausal Osteoporosis
Jiang, Z., Qi, G., He, X., Yu, Y., Cao, Y., Zhang, C., Zou, W., & Yuan, H. (2024) · Advanced Science · doi:10.1002/advs.202307388 · Cited by 146
Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia
Voskaridou, E., Terpos, E., Spina, G., Palermos, J., Rahemtulla, A., Loutradi, A., & Loukopoulos, D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04657.x · Cited by 105
“…recently recognized as the final mediator of osteoclastogenesis, which plays an important role in the pathogenesis of osteoporosis and bone destruction accompanying the menopause, rheumatoid arthritis and multiple myeloma (Haynes et al, 2001; Eghbali-Fatourechi et al, 2003; Terpos et al, 2003b).”
BackgroundHow B cells influence bone biology in health and disease
Horowitz, M. C., Fretz, J. A., & Lorenzo, J. A. (2010) · Bone · doi:10.1016/j.bone.2010.06.011 · Cited by 105
“However, this response does not appear involved in the bone loss that occurs after estrogen withdrawal in humans because increases in B cells were not found in postmenopausal women who had their estrogen replacement stopped [72].”
BackgroundTumor Necrosis Factor-α Mediates Osteopenia Caused by Depletion of Antioxidants
Jagger, C. J., Lean, J. M., Davies, J. T., & Chambers, T. J. (2005) · Endocrinology · doi:10.1210/en.2004-1058 · Cited by 104
“Several mechanisms have been suggested to account for the increase in resorption, including direct effects of estrogen on osteoclasts (2–4), up-regulation of the osteoclast-inductive cytokine receptor activator of nuclear factor-B (NFB) ligand ( 5 ), and downregulation of its decoy receptor osteoprotegerin in osteobla…”
BackgroundBody, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1223-4 · Cited by 116
“RANKL expression is indeed significantly higher in bone marrow cells isolated from early untreated postmenopausal women than in cells obtained from pre- or postmenopausal women treated with estrogens [148].”
BackgroundSclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
Gatti, D., Viapiana, O., Fracassi, E., Idolazzi, L., Dartizio, C., Povino, M. R., Adami, S., & Rossini, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1681 · Cited by 102
“RANKL is mainly produced by osteoblasts and acts through the receptor activator of NF-kB (RANK) found on osteoclasts and preosteoclasts.((11)) RANKL interacts with RANK and stimulates activation of osteoclasts, leading to augmented bone resorption.”
BackgroundCellular senescence and the skeleton: pathophysiology and therapeutic implications
Khosla, S., Farr, J. N., & Monroe, D. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154888 · Cited by 100
“These fundamental developments in bone biology provided a novel therapeutic target, RANKL, which was also found to be increased on multiple cell types, including osteoblast-lineage cells, in the bone marrow of postmenopausal women (3).”
BackgroundSelf-citationBone Remodeling and the Microbiome
Pacifici, R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031203 · Cited by 101
“Many cell types have been shown to be generators of RANKL, including hemopoietic cells, T cells, B cells, osteoblastic cells, and osteocytes (Eghbali-Fatourechi et al. 2003; Taxel et al. 2008; Xiong et al. 2011).”
BackgroundThe impact of bone marrow adipocytes on osteoblast and osteoclast differentiation
Muruganandan, S., & Sinal, C. J. (2014) · IUBMB Life · doi:10.1002/iub.1254 · Cited by 114
“Experimental and clinical studies have reported that estrogen-deficient females or androgen-deficient males have increased RANKL in both peripheral circulation and bone marrow plasma, resulting in increased bone resorption, bone loss, and osteoporosis (62,63).”
BackgroundAnastasilakis, A. D., Toulis, K. A., Goulis, D. G., Pοlyzos, S. A., Delaroudis, S., Giomisi, A., & Terpos, E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1224109 · Cited by 109
Jiang, Y., Mishima, H., Sakai, S., Liu, Y., Ohyabu, Y., & Uemura, T. (2008) · Journal of Orthopaedic Research® · doi:10.1002/jor.20623 · Cited by 108
Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98
“[9], which is likely to be the result of the actions of other cytokines.”
BackgroundInfluentialFujiwara, Y., Piemontese, M., Liu, Y., Thostenson, J. D., Xiong, J., & O'Brien, C. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.742452 · Cited by 99
“Comparison of bone marrow cells from pre-menopausal, post-menopausal, and estrogen-treated post-menopausal women revealed higher levels of RANKL on the surface of B cells in post-menopausal women not receiving estradiol (42).”
BackgroundWang, Z., Chen, K., Wu, C., Chen, J., Pan, H., Liu, Y., Wu, P., Yuan, J., Huang, F., Lang, J., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab194 · Cited by 111
Rifas, L., & Weitzmann, M. N. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24877 · Cited by 105
Ofotokun, I., McIntosh, E. B., & Weitzmann, M. N. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0099-z · Cited by 107
“activated lymphocytes have been implicated as key protagonists of the bone loss associated with pathologies as diverse as postmenopausal osteoporosis [10, 55, 56], rheumatoid arthritis [2], and in alveolar bone loss associated with periodontal infection [3, 54].”
BackgroundPostmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link
Sapir‐Koren, R., & Livshits, G. (2017) · Bone · doi:10.1016/j.bone.2017.06.020 · Cited by 106
“[68] convincingly demonstrated that RANKL expressionwas amplified in early postmenopausalwomen as compared”
Ofotokun, I., Titanji, K., Vunnava, A., Roser‐Page, S., Vikulina, T., Villinger, F. J., Rogers, K. A., Sheth, A. N., Lahiri, C. D., Lennox, J. L., et al. (2016) · AIDS · doi:10.1097/qad.0000000000000918 · Cited by 104
“Interestingly, chronic inflammation associated with CD4þ T-cell activation is an established mechanism for bone loss in multiple pathological situations including periodontal disease and postmenopausal osteoporosis [36–40].”
Molecular and cellular mechanisms linking air pollution and bone damage
Prada, D., López, G., Solleiro-Villavicencio, H., García-Cuellar, C. M., & Baccarelli, A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109465 · Cited by 106
“IL-17 is a cytokine mainly secreted by Th17 lymphocytes and has an important role in bone metabolism because it promotes the release of RANKL by osteoblasts and osteocytes.”
BackgroundInfluentialDrugs for the management of osteoporosis: a review.
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2011) · PubMed · Cited by 95
You, Y., Lin, C., Liang, H., Lee, S.-H., Tsai, K., Chiou, J., Chen, Y., Tsao, C.-K., & Chen, J. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2018 · Cited by 99
“In addition, estrogen deficiency also induces the upregulation of receptor activator of NF‐kB ligand (RANKL) in bone marrow cells, which results in increased bone resorption.((40)) Therefore, estrogen deficiency attributable to menopause may explain the significant association between the metabolites identified in the…”
BackgroundGlucocorticoid-Induced Osteoporosis: Why Kids Are Different
Ward, L. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00576 · Cited by 104
“RANKL is an essential mediator of osteoclast formation, function and survival (120).”
BackgroundGender in Endocrine Diseases: Role of Sex Gonadal Hormones
Lauretta, R., Sansone, M., Sansone, A., Romanelli, F., & Appetecchia, M. (2018) · International Journal of Endocrinology · doi:10.1155/2018/4847376 · Cited by 107
“Estrogens inhibit generation and activity of osteoclasts through an upregulation of osteoprotegerin, decrease T-cell activation and consequently also interferon-γ release by T-cells, and increase intestinal calcium absorption [71, 72].”
BackgroundCheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309690200 · Cited by 92
The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease
Marcadet, L., Bouredji, Z., Argaw, A., & Frenette, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.903657 · Cited by 108
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection
Jones, D., Glimcher, L. H., & Aliprantis, A. O. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46262 · Cited by 91
RANKing c-Jun in osteoclast development
Teitelbaum, S. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422644 · Cited by 90
Immune changes in post-menopausal osteoporosis: the Immunos study
Breuil, V., Ticchioni, M., Testa, J., Roux, C. H., Ferrari, P. P., Breittmayer, J. P., Albert-Sabonnadière, C., Durant, J., Perreti, F. D., Bernard, A., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1018-7 · Cited by 91
“In a previous study, Eghbali-Fatourechi and colleagues reported an increase in RANKL expression of T cells in estrogen deficient women that directly correlated with increased bone resorption markers and inversely with serum estradiol [40].”
BackgroundMatrine prevents bone loss in ovariectomized mice by inhibiting RANKL‐induced osteoclastogenesis
Chen, X., Zhi, X., Pan, P., Cui, J., Cao, L., Weng, W., Zhou, Q., Wang, L. Q., Zhai, X., Zhao, Q., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700316r · Cited by 90
“During the pathogenesis of PMOP, overactivated osteoclastogenesis with excessive bone resorption is one important factor (24).”
BackgroundRole of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss
Ofotokun, I., Titanji, K., Vikulina, T., Roser‐Page, S., Yamaguchi, M., Zayzafoon, M., Williams, I. R., & Weitzmann, M. N. (2015) · Nature Communications · doi:10.1038/ncomms9282 · Cited by 89
Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases
Murakami, T., Nakaminami, Y., Takahata, Y., Hata, K., & Nishimura, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105365 · Cited by 95
Mercuri, L. G. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.03.056 · Cited by 91
Westenfeld, R., Schlieper, G., Woltje, M., Gawlik, A., Brandenburg, V., Rutkowski, P., Floege, J., Jahnen-Dechent, W., & Ketteler, M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr214 · Cited by 84
“Conversely, increased RANKL signalling has been consistently observed in demineralizing diseases with enhanced osteoclast activity in humans [11, 12].”
BackgroundResultPacifici, R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12969 · Cited by 82
Pathophysiology of osteoporosis
Sipos, W., Pietschmann, P., Rauner, M., Kerschan‐Schindl, K., & Patsch, J. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0647-y · Cited by 114
“marrow cells, which is an important determinant of increased bone resorption [13], whereas estrogen itself”
BackgroundDeer Antlers as a Model of Mammalian Regeneration
Price, J. S., Faucheux, C., & Allen, S. (2005) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)67001-9 · Cited by 89
Bonaccorsi, G., Piva, I., Greco, P., & Cervellati, C. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_524_18 · Cited by 88
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Zhang, N., Zhang, Z., Yu, Y., Zhuo, Z., Zhang, G., & Zhang, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00325 · Cited by 91
Estrogens and phytoestrogens in body functions
Ceccarelli, I., Bioletti, L., Peparini, S., Solomita, E., Ricci, C., Casini, I., Miceli, E., & Aloisi, A. M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.007 · Cited by 91
D'Amelio, P., Grimaldi, A., Pescarmona, G. P., Tamone, C., Roato, I., & Isaia, G. (2005) · The FASEB Journal · doi:10.1096/fj.04-2214fje · Cited by 80
“An increased cytokine production in supernatants of PBMC cultures after menopause has also been demonstrated (11–13), with an increase in bone resorbing activity in these cultures (13); furthermore, a recent study of ex vivo cultures of bone marrow demonstrates an increase in RANKL expression in mononuclear cells of b…”
ResultFarr, J. N., Charkoudian, N., Barnes, J. N., Monroe, D. G., McCready, L. K., Atkinson, E. J., Amin, S., Melton, L. J., Joyner, M. J., & Khosla, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2381 · Cited by 79
Self-citationAge-related bone diseases: Role of inflammaging
Bi, J., Zhang, C., Lu, C., Mo, C., Zeng, J., Yao, M., Jia, B., Liu, Z., Yuan, P., & Xu, S. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103169 · Cited by 93
Pelle, D. W., Ringler, J. W., Peacock, J. D., Kampfschulte, K., Scholten, D. J., Davis, M. M., Mitchell, D. S., & Steensma, M. R. (2014) · Translational research · doi:10.1016/j.trsl.2014.03.005 · Cited by 80
Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77
Dysregulation of ectonucleotidase-mediated extracellular adenosine during postmenopausal bone loss
Shih, Y.-R. V., Liu, M., Kwon, S. K., Iida, M., Gong, Y., Sangaj, N., & Varghese, S. (2019) · Science Advances · doi:10.1126/sciadv.aax1387 · Cited by 77
“During postmenopausal osteoporosis, reduced production of estradiol (E2) disturbs bone homeostasis due to altered estrogen receptor (ER) signaling, resulting in decreased osteoblast (30, 31) and increased osteoclast activities (32).”
BackgroundRole of RANKL in bone diseases
Anandarajah, A. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.10.007 · Cited by 84
Osteoporosis and the Potential of Cell-Based Therapeutic Strategies
Macías, I., Alcorta-Sevillano, N., Rodríguez, C. I., & Infante, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051653 · Cited by 82
“Estrogens has been demonstrated to also modulate lymphocytes; its presence suppresses RANKL production in T and B lymphocytes [168], the lack of estrogens increases the release of pro-osteoclastogenic cytokines (tumor necrosis factor α (TNF-α) and RANKL) by activated T lymphocytes [169,170] and are also associated to…”
BackgroundYun, A. J., & Lee, P. Y. (2004) · Medical Hypotheses · doi:10.1016/s0306-9877(03)00326-8 · Cited by 76
“ceptor activator of nuclear factor jB (RANK) have been implicated in osteoclast activity in conjunction with estrogen, 1,25(OH)2D3, and parathyroid hormone [10].”
BackgroundStern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 81
“Mean values using the less sensitive assays ranged from 7 (3) to 26 pg/ml (20, 21, 36 , 37).”
MethodOsteomicrobiology: The influence of gut microbiota on bone in health and disease
Jones, R. M., Mullé, J. G., & Pacifici, R. (2017) · Bone · doi:10.1016/j.bone.2017.04.009 · Cited by 82
Bhadricha, H., Patel, V. V., Singh, A. K., Savardekar, L., Patil, A. D., Surve, S. V., & Desai, M. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-95640-0 · Cited by 82
Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
Wang, H., Luo, Y., Wang, H., Li, F., Yu, F., & Ye, L. (2023) · MedComm · doi:10.1002/mco2.244 · Cited by 88
Inflammation and gut dysbiosis as drivers of CKD–MBD
Evenepoel, P., Stenvinkel, P., Shanahan, C. M., & Pacifici, R. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00736-7 · Cited by 90
T-cells and B-cells in osteoporosis
Weitzmann, M. N. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000103 · Cited by 75
“In the human system, however, increased RANKL production by both B and T-cells has been reported in postmenopausal women [19], although another study found significant increases in both TNFa and RANKL production by T-cells derived from osteoporotic postmenopausal patients, compared with nonosteoporotic postmenopausal…”
ResultNovel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
Rinotas, V. E., Niti, A., Dacquin, R., Bonnet, N., Stolina, M., Han, C.-Y. E., Kostenuik, P. J., Jurdic, P., Ferrari, S., & Douni, E. K. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2112 · Cited by 80
“In addition, estrogen or androgen deficiency in humans and rodents leads to increased RANKL expression that is possibly associated with increased bone loss and risk of fractures,((13,14)) providing a rationale for the development of RANKL‐targeted therapies.”
BackgroundA review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
Miller, P. D. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11424220 · Cited by 76
“RANK-L, a glycoprotein produced in the osteoblast, is a member of the superfamily of ligands, and is also known as a tumor necrosis factor (TNF) activation-induced cytokine and osteoclast activator [Bekker et al. 2004; Boyle et al. 2003; Eghbali-Fatourechi et al. 2003; Suda et al. 1999].”
BackgroundVoskaridou, E., Anagnostopoulos, A., Konstantopoulos, K., Stoupa, E., Spyropoulou, E., Kiamouris, C., & Terpos, E. (2006) · PubMed · Cited by 76
Signaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System
Tanaka, S. (2007) · American Journal of Nephrology · doi:10.1159/000106484 · Cited by 85
“reported that estrogen can directly suppress RANKL and M-CSF-induced differentiation from bone marrow cells. These preclinical studies suggest that estrogen modulates osteoclast differentiation by regulating the RANKL/RANK/OPG system. Several clinical investigations also support the possible role of the RANKL/RANK/OPG…”
BackgroundAcute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes
Maresova, K. B., Pavelká, K., & Stepan, J. J. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9684-4 · Cited by 78
“Simultaneously, we observed only a trend to increase in serum sRANKL, which is reminiscent of the poor and nonconsistent association between circulating OPG and RANKL with biochemical markers of bone turnover and BMD [42], although when measured in the bone marrow high correlations can be observed [43].”
Martini, G., Gennari, L., Merlotti, D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Valleggi, F., & Nuti, R. (2007) · Bone · doi:10.1016/j.bone.2006.08.003 · Cited by 72
“In postmenopausal women OPG increases both in serum and bone [7,8] whereas RANKL is higher in bone marrow stromal cells without any difference in serum levels if compared to premenopausal values [9].”
BackgroundTargeting the RANKL/RANK/OPG Axis for Cancer Therapy
Ming, J., Cronin, S. J. F., & Penninger, J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01283 · Cited by 84
“Nevertheless, it has been reported in postmenopausal women that increased T cell activity and increased RANKL production by T cells are associated with osteoporosis (68, 69).”
BackgroundSenile osteoporosis: Is it an immune-mediated disease?
Martinis, M. D., Benedetto, M. C. D., Mengoli, L. P., & Ginaldi, L. (2006) · Inflammation Research · doi:10.1007/s00011-006-6034-x · Cited by 76
“[36] Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL,”
BackgroundRANKL Regulates Fas Expression and Fas-Mediated Apoptosis in Osteoclasts
Wu, X., Pan, G., McKenna, M. A., Zayzafoon, M., Xiong, W., & McDonald, J. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041022 · Cited by 72
“A representative TRACP stain shows no TRACP+ cells and no multinucleated cells in cultures without RANKL.”
BackgroundInfluentialLiu, J., Zhao, H., Ning, G., Zhao, Y. J., Chen, Y., Zhang, Z., Sun, L., Xu, M.-Y., & Chen, J. L. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0007-2 · Cited by 77
Maroufi, N. F., Ghorbanihaghjo, A., Sayyah-Melli, M., Vaezi, M., Mehrabani, Z. H. A., Amirkhiz, M. B., & Rashtchizadeh, N. (2017) · PubMed Central · Cited by 70
From latency to overt bone metastasis in breast cancer: potential for treatment and prevention
Salvador, F., Lope, A. L., & Gomis, R. R. (2019) · The Journal of Pathology · doi:10.1002/path.5292 · Cited by 76
“ERα and ERβ are highly expressed in both osteoblasts and osteoclast lineages and are thought to be pivotal in bone cell differentiation [29]; post-menopause, paracrine bone morphogens and activins take over [30].”
BackgroundBone structure and metabolism in a rodent model of male senile osteoporosis
Pietschmann, P., Skalicky, M., Kneissel, M., Rauner, M., Hofbauer, G. F. L., Stupphann, D., & Viidik, A. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.08.008 · Cited by 82
Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice
Lloyd, S. A. J., Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Lau, A. G., Morony, S., Stolina, M., Asuncion, F., & Bateman, T. A. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9133-6 · Cited by 77
“One potential etiologic factor that may contribute to this high turnover state is RANKL [18], a TNF family member that is essential for osteoclast activation, differentiation, and survival [3, 8].”
BackgroundMethodInfluentialThe G-Protein-Coupled Receptor GPR103 Regulates Bone Formation
Baribault, H., Danao, J., Gupte, J., Li, Y., Sun, B., Richards, W. G., & Tian, H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.26.2.709-717.2006 · Cited by 75
“The molecular mechanisms underlying osteoclastogenesis have been largely elucidated (for a review, see reference 2). They involved growth and differentiation factors such as macrophage colony-stimulating factor; adhesion molecules such as osteopontin and its receptor, v3 integrin; the activation of osteoclasts by a tu…”
BackgroundEngineered extracellular vesicles for bone therapy
Jiang, Y., Li, J., Xu, X. J., Yin, Z., Xu, K., & Su, J. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101487 · Cited by 74
Genetic Polymorphisms of OPG, RANK, and ESR1 and Bone Mineral Density in Korean Postmenopausal Women
Choi, J. Y., Shin, A., Park, S., Chung, H. W., Cho, S. I., Shin, C. S., Kim, H., Lee, K., Lee, K., Kang, C., et al. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0264-0 · Cited by 76
“(ESR1) [6–11].”
Lee, M.-Y., Huang, J., Chen, Y., Aplin, J., Wu, Y., Chen, C., Chen, P.-C., & Chen, C.-P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006913 · Cited by 68
“This parameter is measured independently from the proportion of positive cells, estimated as the difference between the mean fluorescence (the surface concentration of integrin molecules) of positive cells and that of the control samples, regardless of the frequency of positive cells [32].”
BackgroundAzizieh, F. Y., Shehab, D., Al-Jarallah, K. F., Gupta, R., & Raghupathy, R. (2019) · Biomarker Insights · doi:10.1177/1177271919843825 · Cited by 79
Osteoclasts—the innate immune cells of the bone
Wu, Y., Humphrey, M. B., & Nakamura, M. C. (2008) · Autoimmunity · doi:10.1080/08916930701693180 · Cited by 67
“[110] Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ,”
BackgroundFuruya, Y., Mori, K., Ninomiya, T., Tomimori, Y., Tanaka, S., Takahashi, N., Udagawa, N., Uchida, K., & Yasuda, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246280 · Cited by 74
Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q., Asuncion, F., Tan, H., Grisanti, M. S., Dwyer, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.06.011 · Cited by 69
“Estradiol has been shown to inhibit RANKL expression in bone marrow cultures [44] and in bone marrow cells harvested from postmenopausal subjects after hormone replacement therapy [37].”
BackgroundResult
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.